SCHEMBL19065340

SCHEMBL19065340

CCn1cc(-c2ccnc(-c3ncc(-c4ccccc4)[nH]3)c2)cn1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 5/20 0.50
PIM1 P11309 6/20 0.46
SCN2A Q99250 2/20 0.43
HPGDS O60760 4/20 0.43
ACSS2 Q9NR19 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMPD3 Q9NY59 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19066083 0.91 NPY5R (0.48) NPY5RPIM1SCN2AHPGDSCYP1A2
Trifluoroacetic Acid SCHEMBL29675408 0.91 NPY5R (0.42) NPY5RPIM1SCN2AHPGDSACSS2
Trifluoroacetic Acid SCHEMBL19065605 0.91 NPY5R (0.42) NPY5RPIM1SCN2AHPGDSACSS2
SCHEMBL19065711 0.88 L3MBTL1 (0.54) NPY5RSCN2AHPGDS
SCHEMBL19065511 0.86 NPY5R (0.47) NPY5RPIM1SCN2AHPGDS
SCHEMBL19065641 0.85 NPY5R (0.53) NPY5RPIM1SCN2AHPGDS
SCHEMBL19065354 0.84 NPY5R (0.45) NPY5RSCN2AHPGDSKDM4EMAPT
SCHEMBL19065720 0.84 NPY5R (0.45) NPY5RPIM1SCN2AHPGDS
SCHEMBL19065676 0.84 SCN2A (0.48) NPY5RSCN2AHPGDSCYP3A4CYP2C9
SCHEMBL19065269 0.84 PDK2 (0.46) NPY5RSCN2AHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952367-B2 Pyridine and pyridimine compounds as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2024-04-09 US claimed
US-20220227736-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION 2022-07-21 US claimed
US-11352340-B2 Pyridine and pyridimine compounds as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2022-06-07 US claimed
EP-3792256-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2021-03-17 EP claimed
EP-3400221-B1 PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS INCYTE CORP (US) 2020-08-26 EP claimed
EP-3400221-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2018-11-14 EP claimed
WO-2017120194-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2017-07-13 WO claimed
US-20170190689-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION 2017-07-06 US claimed
EP-3792256-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2021-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227736-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS PIK3CG, PIK3CD, PIK3CB NPY5R 4040/4885PIM1 777/4885SCN2A 1369/4885
US-11352340-B2 Pyridine and pyridimine compounds as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3CB NPY5R 4040/4885PIM1 777/4885SCN2A 1369/4885
US-20170190689-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS PIK3CG, PIK3CD, PIK3CB NPY5R 4040/4885PIM1 777/4885SCN2A 1369/4885
US-11952367-B2 Pyridine and pyridimine compounds as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3CB NPY5R 4040/4885PIM1 777/4885SCN2A 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.